[PDF] Top 20 Configuración de la familia en su diversidad

... of patients with good performance status and organ function ...94 patients with relapsed NSCLC treated in the second-line setting showed a median survival of 6 months and 1-year OS rate of ...only ... See full document

... Japanese patients. Adjuvant chemotherapy is the standard of therapy for some patients with stage I, II, and III breast ...Japanese patients with NSCLC in a single insti- ...of ... See full document

... with gemcitabine plus carboplatin, 398 patients with advanced, nonprogressive NSCLC were randomized to receive immediate docetaxel or at the point of disease ...progression. Patients in ... See full document

... in patients with advanced NSCLC and good performance status (score 0 – 1) was chemotherapy combining a platinum compound (cisplatin or carboplatin) with a third-generation drug such as ... See full document

... for patients undergoing afatinib ...against chemotherapy-induced diarrhea and oral ...29 patients with epidermal growth factor receptor mutation-positive non-small cell ... See full document

... many patients do not respond to VEGF-targeted therapy, and for those that do, responses are short-lived, and resistance develops in the majority of ...in patients with advanced stage non–small ... See full document

... with gemcitabine, paclitaxel or docetaxel ...was gemcitabine, so this was adopted for the trial for all types of ...to gemcitabine in non- squamous NSCLC ...that patients with epidermal ... See full document

... First-line chemotherapy included cisplatin or carboplatin in combination with one of the following agents: pemetrexed (nonsquamous histology), vinorelbine, gemcitabine, or pacli- ...taxel. ... See full document

... Thirty-eight patients had stage IV tumors. Thirty- seven patients had adenocarcinoma (including 6 alveolar carcinoma ...Fourteen patients had squamous- cell ...Thirty-two patients ... See full document

... platinum-based chemotherapy, HR ...of patients exposed to both chemotherapy and erlotinib (in any line of treatment) was ...in patients exposed to erlotinib only, and 11.7 months in ... See full document

... of gemcitabine (10 mg/m 2 /min), ORR ranged between 20% and 47% ...better patients’ characteristics, as 60% and 46.7% of patients in the standard arm and FDR arm respectively, were stage IIIB ...of ... See full document

... gefitinib plus chemotherapy and cetuximab plus chemotherapy on the treatment of advanced non-small cell lung cancer, but little is known about the ... See full document

... Bevacizumab plus chemotherapy was approved by the US Food and Drug Administration (FDA) as a first-line treatment for advanced nonsquamous, non-small-cell lung cancer ... See full document

... in cancer treatment for several cancer ...cytotoxic chemotherapy for indications including metastatic colorectal cancer, non-small-cell lung cancer, breast ... See full document

... maintenance chemotherapy with carboplatin and etoposide may exceed that of standard cisplatin and etoposide for four to six cycles in extensive stage ...the patients in this study were consecutive ... See full document

... adjuvant chemotherapy after surgery from the results that the meta-analysis of surgery plus chemotherapy versus surgery alone was based on 34 trial com- parisons and 8447 patients (3323 ... See full document

... [1]. Lung cancer has a death rate, greater than that attributed to colorectal, breast and prostate cancers combined ...[2].Non small cell lung cancer (NSCLC) constitutes ... See full document

... 303 patients to be PTEN-positive as assessed by immunohistochemical ...analysis. Patients in both the cetuximab-plus-chemotherapy and chemotherapy-alone groups experienced better ... See full document

... ment, there are still some unanswered questions, mainly in terms of patient selection. Optimal selection of patients who would benefit from cetuximab is challenging and is key in its further development as a ... See full document

... 240 patients with measurable metastatic triple-negative breast cancer and treatment naive for metastatic disease will be randomized 1:1:1 (stratified by disease-free interval: ≤ 1 versus > 1 year) to nab ... See full document